A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results

Strasser, S.; Roberts, S.; Angus, P.; Chan, H. L. Y.; Fung, S.; Seto, W. K.; Chuang, W. L.; Chen, C. Y.; Kim, H. J.; Hui, A. J.; Janssen, H. L. A.; Chowdhury, A.; Tsang, T. Y. O.; Mehta, R.; Gane, E.; Flaherty, J. F.; Massetto, B.; Kitrinos, K.; Dinh, P.; Subramanian, G. M.; Mchutchison, J. G.; Lim, Y. S.; Acharya, S. K.; Agarwal, K.

Links

ORCID

Tools

Export citation

Search in Google Scholar

A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results

Journal article published in 2016 by S. Strasser, S. Roberts, P. Angus, H. L. Y. Chan, S. Fung, W. K. Seto, W. L. Chuang, C. Y. Chen, H. J. Kim, A. J. Hui, H. L. A. Janssen, A. Chowdhury, T. Y. O. Tsang, R. Mehta, E. Gane and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload